jinbeixin firsekibart injection 200 mg per vial or 150 mg per vial

Description

Indication & Scope

JinBeiXin (Firsekibart) is a fully human anti-IL-1β monoclonal antibody developed for the treatment of acute gouty arthritis attacks.

Mechanism: Firsekibart specifically binds to interleukin-1β (IL-1β), blocking IL-1β-mediated inflammatory signaling and reducing inflammatory mediator production associated with gout attacks.
Drug class: Fully human anti-IL-1β monoclonal antibody.
Clinical use: Treatment of acute gouty arthritis attacks in adults with contraindications, intolerance, or inadequate response to conventional anti-inflammatory therapies.

Specification

Generic Name	Firsekibart
Brand Name	JinBeiXin®
Ingredient	Each vial contains firsekibart.
Dosage Form	Solution for Injection.
Package	One vial (150 mg/vial; 200 mg/vial).
Conditions Treated	Treatment of acute gouty arthritis attacks in adults who are contraindicated, intolerant, or have inadequate response to non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine, and who are not suitable for repeated corticosteroid use.
Taboos	Hypersensitivity to firsekibart or any component of the product.
Place of origin	China
Prescription type	Prescription Drug (Rx)
Storage Conditions	Refer to the approved package labeling.
Manufacturer	Changchun GeneScience Pharmaceutical Co., Ltd.
Registration Authority	National Medical Products Administration (NMPA), China
Approval number	Changchun GeneScience Pharmaceutical Co., Ltd.
Date of Revision	2026
Shelf Life	Refer to the approved package labeling

How to use ?

Recommended Dose: 200 mg administered by subcutaneous injection as a single dose for the treatment of acute gouty arthritis attacks.

Time: Administer a single subcutaneous injection according to the approved treatment regimen.

Instructions for use: Administer by subcutaneous injection under the supervision of a healthcare professional. Use according to the approved prescribing information.

Interaction: No clinically significant drug interaction information has been established. Refer to the approved package labeling for details.

Side effects: The most commonly reported adverse reactions include hypertriglyceridemia, hypercholesterolemia, elevated alanine aminotransferase (ALT), and elevated aspartate aminotransferase (AST).

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support

Certificate of Analysis

GMP Certificate

Commercial Invoice

Packing List & CPP

Cold Chain Logistics

Customs Documentation

Scientific and regulatory sources

1.WHO References

2.NMPA

3.FDA

4.EMA

FAQ

What is the recommended dose of JinBeiXin?

The recommended dose is 200 mg administered by a single subcutaneous injection for the treatment of acute gouty arthritis attacks.

Can JinBeiXin be used to lower uric acid levels?

No. JinBeiXin is an anti-inflammatory therapy used to control acute gout attacks and does not directly lower blood uric acid levels.

Who may be suitable for JinBeiXin treatment?

It may be considered for adults with acute gouty arthritis who have contraindications, intolerance, or insufficient response to NSAIDs and/or colchicine, or who are unsuitable for repeated corticosteroid use.

What are the common adverse reactions of Firsekibart?

Reported adverse reactions include lipid abnormalities (such as increased triglycerides and cholesterol) and elevated liver enzymes. Patients should follow medical advice and monitoring recommendations during treatment.